These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Bertin-Ciftci J; Barré B; Le Pen J; Maillet L; Couriaud C; Juin P; Braun F Cell Death Differ; 2013 May; 20(5):755-64. PubMed ID: 23429261 [TBL] [Abstract][Full Text] [Related]
24. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
25. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956 [TBL] [Abstract][Full Text] [Related]
26. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799 [TBL] [Abstract][Full Text] [Related]
27. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Cao Y; Yang G; Hunter ZR; Liu X; Xu L; Chen J; Tsakmaklis N; Hatjiharissi E; Kanan S; Davids MS; Castillo JJ; Treon SP Br J Haematol; 2015 Jul; 170(1):134-8. PubMed ID: 25582069 [No Abstract] [Full Text] [Related]
28. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Mazumder S; Choudhary GS; Al-Harbi S; Almasan A Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702 [TBL] [Abstract][Full Text] [Related]
29. Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl-2 antagonist-induced respiratory changes. Clerc P; Ge SX; Hwang H; Waddell J; Roelofs BA; Karbowski M; Sesaki H; Polster BM Br J Pharmacol; 2014 Apr; 171(8):1988-99. PubMed ID: 24206264 [TBL] [Abstract][Full Text] [Related]
30. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664 [TBL] [Abstract][Full Text] [Related]
31. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843 [TBL] [Abstract][Full Text] [Related]
32. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623 [TBL] [Abstract][Full Text] [Related]
33. Targeting multiple arms of the apoptotic regulatory machinery. Dai Y; Grant S Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392 [TBL] [Abstract][Full Text] [Related]
34. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153 [TBL] [Abstract][Full Text] [Related]
35. Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Shamas-Din A; Bindner S; Chi X; Leber B; Andrews DW; Fradin C Biochem J; 2015 May; 467(3):495-505. PubMed ID: 25714678 [TBL] [Abstract][Full Text] [Related]
36. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182 [TBL] [Abstract][Full Text] [Related]
37. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808 [TBL] [Abstract][Full Text] [Related]
38. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. Liu Q; Leber B; Andrews DW Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112 [TBL] [Abstract][Full Text] [Related]
39. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. Wang H; Yang YB; Shen HM; Gu J; Li T; Li XM PLoS One; 2012; 7(12):e52483. PubMed ID: 23285061 [TBL] [Abstract][Full Text] [Related]